Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Powering a prospective melanoma chemoprevention trial in high-risk cohorts.

Varedi A, Bishop MD, Boucher KM, Kim CC, Grossman D.

Int J Dermatol. 2019 Nov;58(11):e232-e234. doi: 10.1111/ijd.14538. Epub 2019 Jun 17. No abstract available.

PMID:
31206619
2.

AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.

Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, Holmen SL.

Mol Cancer Res. 2019 Sep;17(9):1787-1800. doi: 10.1158/1541-7786.MCR-18-1372. Epub 2019 May 28.

PMID:
31138602
3.

A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer.

Stewart RL, Updike KL, Factor RE, Henry NL, Boucher KM, Bernard PS, Varley KE.

Cancer Res. 2019 Jul 1;79(13):3466-3478. doi: 10.1158/0008-5472.CAN-18-3014. Epub 2019 May 2.

PMID:
31048497
4.

Parent and child perspectives on perceived barriers to child sun protection and their association with sun protection strategies among children of melanoma survivors.

Wu YP, Parsons BG, Aspinwall LG, Hay JL, Boucher KM, Caputo H, Mooney R, Grossman D, Leachman SA.

Pediatr Dermatol. 2019 May;36(3):317-323. doi: 10.1111/pde.13796. Epub 2019 Mar 20.

PMID:
30895676
5.

Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.

Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, O'Hare T, Deininger MW.

Clin Cancer Res. 2019 Apr 1;25(7):2323-2335. doi: 10.1158/1078-0432.CCR-18-0959. Epub 2018 Dec 18.

6.

A functional assay-based procedure to classify mismatch repair gene variants in Lynch syndrome.

Drost M, Tiersma Y, Thompson BA, Frederiksen JH, Keijzers G, Glubb D, Kathe S, Osinga J, Westers H, Pappas L, Boucher KM, Molenkamp S, Zonneveld JB, van Asperen CJ, Goldgar DE, Wallace SS, Sijmons RH, Spurdle AB, Rasmussen LJ, Greenblatt MS, de Wind N, Tavtigian SV.

Genet Med. 2019 Jul;21(7):1486-1496. doi: 10.1038/s41436-018-0372-2. Epub 2018 Dec 3.

PMID:
30504929
7.

Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer.

Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S.

Invest New Drugs. 2019 Jun;37(3):482-489. doi: 10.1007/s10637-018-0645-2. Epub 2018 Oct 10.

PMID:
30302599
8.

Small RNA sequencing of sessile serrated polyps identifies microRNA profile associated with colon cancer.

Kanth P, Hazel MW, Boucher KM, Yang Z, Wang L, Bronner MP, Boylan KE, Burt RW, Westover M, Neklason DW, Delker DA.

Genes Chromosomes Cancer. 2019 Jan;58(1):23-33. doi: 10.1002/gcc.22686. Epub 2018 Nov 18.

PMID:
30265426
9.

Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.

Sample DC, Samadder NJ, Pappas LM, Boucher KM, Samowitz WS, Berry T, Westover M, Nathan D, Kanth P, Byrne KR, Burt RW, Neklason DW.

BMC Gastroenterol. 2018 Jul 16;18(1):115. doi: 10.1186/s12876-018-0841-8.

10.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P.

Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.

11.

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.

Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, Ahorukomeye P, Glenn MJ, Deininger MWN, Boucher KM, Bavisotto LM, Gutierrez-Sanchez G, Kennedy TP, Marcus SG, Shami PJ.

Blood Adv. 2018 Feb 27;2(4):381-389. doi: 10.1182/bloodadvances.2017013391.

12.

Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.

Samadder NJ, Kuwada SK, Boucher KM, Byrne K, Kanth P, Samowitz W, Jones D, Tavtigian SV, Westover M, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Burt RW, Neklason DW.

JAMA Oncol. 2018 May 1;4(5):671-677. doi: 10.1001/jamaoncol.2017.5431.

13.

Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework.

Tavtigian SV, Greenblatt MS, Harrison SM, Nussbaum RL, Prabhu SA, Boucher KM, Biesecker LG; ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI).

Genet Med. 2018 Sep;20(9):1054-1060. doi: 10.1038/gim.2017.210. Epub 2018 Jan 4.

14.

The association between socioeconomic factors and breast cancer-specific survival varies by race.

Agarwal S, Ying J, Boucher KM, Agarwal JP.

PLoS One. 2017 Dec 6;12(12):e0187018. doi: 10.1371/journal.pone.0187018. eCollection 2017.

15.

Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.

Delker DA, Wood AC, Snow AK, Samadder NJ, Samowitz WS, Affolter KE, Boucher KM, Pappas LM, Stijleman IJ, Kanth P, Byrne KR, Burt RW, Bernard PS, Neklason DW.

Cancer Prev Res (Phila). 2018 Jan;11(1):4-15. doi: 10.1158/1940-6207.CAPR-17-0130. Epub 2017 Nov 6.

16.

A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma.

Wu YP, Nagelhout E, Aspinwall LG, Boucher KM, Parsons BG, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Leachman SA.

Patient Educ Couns. 2018 Mar;101(3):452-459. doi: 10.1016/j.pec.2017.10.008. Epub 2017 Oct 19.

17.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D.

Melanoma Res. 2017 Oct;27(5):477-484. doi: 10.1097/CMR.0000000000000382.

18.

Diverse Non-genetic, Allele-Specific Expression Effects Shape Genetic Architecture at the Cellular Level in the Mammalian Brain.

Huang WC, Ferris E, Cheng T, Hörndli CS, Gleason K, Tamminga C, Wagner JD, Boucher KM, Christian JL, Gregg C.

Neuron. 2017 Mar 8;93(5):1094-1109.e7. doi: 10.1016/j.neuron.2017.01.033. Epub 2017 Feb 23.

19.

Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma.

Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ.

Surgery. 2017 Jul;162(1):104-111. doi: 10.1016/j.surg.2016.12.029. Epub 2017 Feb 21.

20.

The BREASTrial Stage II: ADM Breast Reconstruction Outcomes from Definitive Reconstruction to 3 Months Postoperative.

Mendenhall SD, Anderson LA, Ying J, Boucher KM, Neumayer LA, Agarwal JP.

Plast Reconstr Surg Glob Open. 2017 Jan 25;5(1):e1209. doi: 10.1097/GOX.0000000000001209. eCollection 2017 Jan.

21.

A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo.

Cassidy PB, Liu T, Florell SR, Honeggar M, Leachman SA, Boucher KM, Grossman D.

Cancer Prev Res (Phila). 2017 Jan;10(1):36-44. doi: 10.1158/1940-6207.CAPR-16-0162. Epub 2016 Dec 5.

22.

Long-term health effects among testicular cancer survivors.

Hashibe M, Abdelaziz S, Al-Temimi M, Fraser A, Boucher KM, Smith K, Lee YA, Rowe K, Rowley B, Daurelle M, Holton AE, VanDerslice J, Richiardi L, Bishoff J, Lowrance W, Stroup A.

J Cancer Surviv. 2016 Dec;10(6):1051-1057. Epub 2016 May 11.

23.

Factors associated with early adoption of the HPV vaccine in US male adolescents include Hispanic ethnicity and receipt of other vaccines.

Kepka D, Ding Q, Hawkins AJ, Warner EL, Boucher KM.

Prev Med Rep. 2016 May 25;4:98-102. doi: 10.1016/j.pmedr.2016.05.014. eCollection 2016 Dec.

24.

Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype.

Kanth P, Bronner MP, Boucher KM, Burt RW, Neklason DW, Hagedorn CH, Delker DA.

Cancer Prev Res (Phila). 2016 Jun;9(6):456-65. doi: 10.1158/1940-6207.CAPR-15-0363. Epub 2016 Mar 29.

25.

Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.

Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, Strait E, McKinnon W, Burt RW, Kuwada SK.

JAMA. 2016 Mar 22-29;315(12):1266-75. doi: 10.1001/jama.2016.2522.

26.

Reduction in nevus biopsies in patients monitored by total body photography.

Truong A, Strazzulla L, March J, Boucher KM, Nelson KC, Kim CC, Grossman D.

J Am Acad Dermatol. 2016 Jul;75(1):135-143.e5. doi: 10.1016/j.jaad.2016.02.1152. Epub 2016 Mar 3.

PMID:
26947450
27.

Conditional survival for pediatric and adolescent patients with cancer: Implications for survivorship care.

Kaul S, Kirchhoff AC, Boucher KM, Dietz AC.

Cancer Epidemiol. 2015 Dec;39(6):1071-7. doi: 10.1016/j.canep.2015.09.006. Epub 2015 Oct 1.

PMID:
26427865
28.

ReCAP: Gaps in Insurance Coverage for Pediatric Patients With Acute Lymphoblastic Leukemia.

Smits-Seemann RR, Kaul S, Hersh AO, Fluchel MN, Boucher KM, Kirchhoff AC, Smits-Seemann RR, Kaul S, Hersh AO, Fluchel MN, Boucher KM, Kirchhoff AC.

J Oncol Pract. 2016 Feb;12(2):175-6; e207-14. doi: 10.1200/JOP.2015.005686. Epub 2015 Sep 29.

PMID:
26420890
29.

Efficacy of a Telehealth Intervention on Colonoscopy Uptake When Cost Is a Barrier: The Family CARE Cluster Randomized Controlled Trial.

Steffen LE, Boucher KM, Damron BH, Pappas LM, Walters ST, Flores KG, Boonyasiriwat W, Vernon SW, Stroup AM, Schwartz MD, Edwards SL, Kohlmann WK, Lowery JT, Wiggins CL, Hill DA, Higginbotham JC, Burt R, Simmons RG, Kinney AY.

Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1311-8. doi: 10.1158/1055-9965.EPI-15-0150. Epub 2015 Jun 22.

30.

Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy.

Rudrapatna VK, Morley K, Boucher KM, Pierson AS, Shull CT, Kushner JP, Shami PJ.

Leuk Res. 2015 Aug;39(8):835-9. doi: 10.1016/j.leukres.2015.05.004. Epub 2015 May 18.

PMID:
26038120
31.

The Effect of Radiation on Complication Rates and Patient Satisfaction in Breast Reconstruction using Temporary Tissue Expanders and Permanent Implants.

Anker CJ, Hymas RV, Ahluwalia R, Kokeny KE, Avizonis V, Boucher KM, Neumayer LA, Agarwal JP.

Breast J. 2015 May-Jun;21(3):233-40. doi: 10.1111/tbj.12395. Epub 2015 Mar 15.

32.

The BREASTrial: stage I. Outcomes from the time of tissue expander and acellular dermal matrix placement to definitive reconstruction.

Mendenhall SD, Anderson LA, Ying J, Boucher KM, Liu T, Neumayer LA, Agarwal JP.

Plast Reconstr Surg. 2015 Jan;135(1):29e-42e. doi: 10.1097/PRS.0000000000000758.

PMID:
25539349
33.

The breast reconstruction evaluation of acellular dermal matrix as a sling trial (BREASTrial): design and methods of a prospective randomized trial.

Agarwal JP, Mendenhall SD, Anderson LA, Ying J, Boucher KM, Liu T, Neumayer LA.

Plast Reconstr Surg. 2015 Jan;135(1):20e-8e. doi: 10.1097/PRS.0000000000000809.

PMID:
25539330
34.

Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial.

Kinney AY, Butler KM, Schwartz MD, Mandelblatt JS, Boucher KM, Pappas LM, Gammon A, Kohlmann W, Edwards SL, Stroup AM, Buys SS, Flores KG, Campo RA.

J Natl Cancer Inst. 2014 Nov 5;106(12). pii: dju328. doi: 10.1093/jnci/dju328. Print 2014 Dec.

35.

Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.

Kaur I, Kosak KM, Terrazas M, Herron JN, Kern SE, Boucher KM, Shami PJ.

Pharm Res. 2015 Apr;32(4):1395-406. doi: 10.1007/s11095-014-1542-9. Epub 2014 Oct 18.

36.

Blood pressure, salivary cortisol, and inflammatory cytokine outcomes in senior female cancer survivors enrolled in a tai chi chih randomized controlled trial.

Campo RA, Light KC, O'Connor K, Nakamura Y, Lipschitz D, LaStayo PC, Pappas LM, Boucher KM, Irwin MR, Hill HR, Martins TB, Agarwal N, Kinney AY.

J Cancer Surviv. 2015 Mar;9(1):115-25. doi: 10.1007/s11764-014-0395-x. Epub 2014 Aug 28.

37.

Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers.

Firpo MA, Boucher KM, Mulvihill SJ.

Theor Biol Med Model. 2014 Aug 5;11:34. doi: 10.1186/1742-4682-11-34.

38.

Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.

El-Chaar NN, Piccolo SR, Boucher KM, Cohen AL, Chang JT, Moos PJ, Bild AH.

Mol Oncol. 2014 Oct;8(7):1339-54. doi: 10.1016/j.molonc.2014.05.005. Epub 2014 May 20.

39.

Abstract 6: The BREASTrial: Breast Reconstruction Evaluation of Acellular Dermal Matrix as a Sling Trial, Design and Stage I Outcomes of a Randomized Trial.

Mendenhall SD, Anderson LA, Ying J, Boucher KM, Neumayer LA, Agarwal JP.

Plast Reconstr Surg. 2014 Mar;133(3 Suppl):13-4. doi: 10.1097/01.prs.0000444919.45830.d0. No abstract available.

PMID:
25942117
40.

A population-based study of childhood cancer survivors' body mass index.

Warner EL, Fluchel M, Wright J, Sweeney C, Boucher KM, Fraser A, Smith KR, Stroup AM, Kinney AY, Kirchhoff AC.

J Cancer Epidemiol. 2014;2014:531958. doi: 10.1155/2014/531958. Epub 2014 Jan 9.

41.

Telehealth personalized cancer risk communication to motivate colonoscopy in relatives of patients with colorectal cancer: the family CARE Randomized controlled trial.

Kinney AY, Boonyasiriwat W, Walters ST, Pappas LM, Stroup AM, Schwartz MD, Edwards SL, Rogers A, Kohlmann WK, Boucher KM, Vernon SW, Simmons RG, Lowery JT, Flores K, Wiggins CL, Hill DA, Burt RW, Williams MS, Higginbotham JC.

J Clin Oncol. 2014 Mar 1;32(7):654-62. doi: 10.1200/JCO.2013.51.6765. Epub 2014 Jan 21.

42.

Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp.

Terakedis BE, Anker CJ, Leachman SA, Andtbacka RH, Bowen GM, Sause WT, Grossmann KF, Bowles TL, Noyes RD, Hitchcock YJ, Boucher KM, Shrieve DC.

J Am Acad Dermatol. 2014 Mar;70(3):435-42. doi: 10.1016/j.jaad.2013.10.028. Epub 2013 Dec 24.

PMID:
24373782
43.

Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control.

Ghia AJ, Tward JD, Anker CJ, Boucher KM, Jensen RL, Shrieve DC.

J Radiosurg SBRT. 2014;3(1):43-50.

44.

Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.

Kendrick ZW, Firpo MA, Repko RC, Scaife CL, Adler DG, Boucher KM, Mulvihill SJ.

HPB (Oxford). 2014 Jul;16(7):670-6. doi: 10.1111/hpb.12199. Epub 2013 Dec 6.

45.

Isolation of circulating microRNAs from microvesicles found in human plasma.

Quackenbush JF, Cassidy PB, Pfeffer LM, Boucher KM, Hawkes JE, Pfeffer SR, Kopelovich L, Leachman SA.

Methods Mol Biol. 2014;1102:641-53. doi: 10.1007/978-1-62703-727-3_34.

PMID:
24259003
46.

Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G.

Clin Genitourin Cancer. 2014 Apr;12(2):130-7. doi: 10.1016/j.clgc.2013.09.002. Epub 2013 Sep 28.

47.

Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong.

Campo RA, Agarwal N, LaStayo PC, O'Connor K, Pappas L, Boucher KM, Gardner J, Smith S, Light KC, Kinney AY.

J Cancer Surviv. 2014 Mar;8(1):60-9. doi: 10.1007/s11764-013-0315-5. Epub 2013 Oct 30.

48.

Effect of brachytherapy technique and patient characteristics on cervical cancer implant dosimetry.

Anker CJ, O'Donnell K, Boucher KM, Gaffney DK.

Med Dosim. 2013 Winter;38(4):430-5. doi: 10.1016/j.meddos.2013.06.001. Epub 2013 Aug 22.

PMID:
23973016
49.

Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.

Kaur I, Terrazas M, Kosak KM, Kern SE, Boucher KM, Shami PJ.

J Pharm Pharmacol. 2013 Sep;65(9):1329-36. doi: 10.1111/jphp.12100. Epub 2013 Jul 10.

50.

Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.

Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD.

Target Oncol. 2014 Sep;9(3):195-204. doi: 10.1007/s11523-013-0289-2. Epub 2013 Jul 13. Review.

Supplemental Content

Loading ...
Support Center